Melanotan II comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
The concentration of protein C increases until six months, when the mean level is 60 IU/dL; the level stays low through childhood until it reaches adult levels after adolescence. The half-life of activated protein C is around 15 minutes.
In 2022, more than 1 billion adolescent girls and women suffered from undernutrition, according to UNICEF's 2023 report "Undernourished and Overlooked: A Global Nutrition Crisis in Adolescent Girls and Women". The gender gap in food insecurity more than doubled between 2019 (49 million) and 2021 (126 million). The report shows that globally, 30% of women aged 15–49 years are living with anaemia while 10 per cent of women aged 20–49 years suffer from underweight. South Asia, West and Central Africa and Eastern and Southern Africa are home to 60% of women with anaemia and 65% of women being underweight. In contrast, overweight is affecting more than 35% of women aged 20–49 years, of which 13% are living with obesity. The Middle East and North Africa has the highest prevalence of overweight with 61% affected. North America closely follows at 60%. Fewer than 1 in 3 adolescent girls and women have diets meeting the minimum dietary diversity in the Sudan (10%), Burundi (12%), Burkina Faso (17%) and Afghanistan (26%). In Niger, the percentage of women accessing a minimally diverse diet fell from 53% to 37% between 2020 and 2022. Researchers from the Centre for World Food Studies in 2003 found that the gap between levels of undernutrition in men and women is generally small, but that the gap varies from region to region and from country to country. These small-scale studies showed that female undernutrition prevalence rates exceeded male undernutrition prevalence rates in South/Southeast Asia and Latin America and were lower in Sub-Saharan Africa.
The nobles, in turn, granted portions of their land to vassals, land holders for the king, which created a hierarchal structure of land tenure. The Domesday Book, written in 1086 formalized land ownership and feudal obligations in England, creating a legal framework form resolving disputes over property. Legal obligations under this feudal system included required military service to the land's respective lords. Failure to meet these duties often resulted in forfeiture of land or other penalties. The disputes over land and feudal obligations were resolved in feudal courts. These courts operated at various levels: local, manorial, or baronial - and reinforced the feudal hierarchy by emphasizing the lord's role as the arbiter of justice within his domain.
== Ophthalmic acid is not a biomarker of oxidative stress == OPH has mostly appeared in metabolomics studies correlating changes in its abundance with oxidative stress, following a study from 2006 on acetaminophen overdose in mice. However, this practice should generally be avoided, as there are major issues:
Sources: en.wikipedia.org
Has more cell layers Is less permeable Exhibits more developed intercellular junctions Provides a more substantial physical barrier to microbial invasion This structural difference explains why the junctional epithelium is more actively involved in host–microbe interaction, whereas the sulcular epithelium plays a more protective role.
Debbie Dingell official U.S. House website Debbie Dingell for Congress Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart Appearances on C-SPAN
Carbohydrates – ranging from monosaccharides to polysaccharides and including blood group antigens, hyaluronic acid oligomers and sialic acid residues Peptide/protein – ranging from single amino acids to proteins as large as antibodies Labels – including fluorophores, radioisotopes, biotin, etc. Other – chemical moieties such as maleimide, click residues, PEG, charged compounds Note 1: Multimeric – the presentation of the F residue can be as multimers with controlled spacing and be variable. Note 2: Mass – the mass that can be anchored by an FSL Kode constructs can range from 200 to >1 million Da
==== United States ==== JRT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
In 1999, initiated by the International Olympic Committee to fight against doping in sport, the World Anti-Doping Agency had been founded. After the doping scandal in cycling in the summer 1998 the International Olympic Committee (IOC) decided to establish the WADA to promote, coordinate and monitor the fight of against doping in sport. The headquarters for WADA is in Montreal, Canada. The WADA is the supreme international authority and is allowed to do doping tests and can determine which substances are illegal. In February 2011, the United States Olympic Committee and the Ad Council launched an anti-steroid campaign called Play Asterisk Free aimed at teens. The campaign first launched in 2008 under the name "Don't Be An Asterisk!". In October 2012, the USADA released evidence to corroborate their doping claim against cyclist Lance Armstrong. According to USADA CEO Travis T. Tygart, the evidence against Armstrong includes, "...scientific data and laboratory test results that further prove the use, possession and distribution of performance-enhancing drugs". On 1 November 1989, US Senator Joseph Biden introduced S. 1829, The Steroid Trafficking Act of 1989. The purpose of the act was simple: It would "amend the Controlled Substances Act to further restrict the use of steroids. By designating anabolic steroids as a Schedule II controlled substance, the bill would crack down on illegal steroid use". (Senate Judiciary Committee, 2002, p. 282).
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.